Home V小姐
Over 10 years of professional equity research experience in a major international investment bank.
Biotech Stock Updates
We focus to look at key drivers of biotech stocks' price movement on 21 May 2025. UroGen Pharma (NASDAQ: URGN) announced that the FDA’s Oncologic Drugs Advisory Committee (ODAC) voted 4–5 against the benefit-risk profile of its investigational therapy UGN-102 (mitomycin) for intravesical solution fo CEL-SCI Corporation (NYSE: CVM) announced that it intends to offer to sell shares of its common stock and/or pre-funded warrants in an underwritten public offering. Shares traded down 13% at US$3.95 during after hours Petros Pharmaceuticals (NASDAQ: PTPI) partnered with Innolitics to upgrade its SaaS platform by integrating AI, cybersecurity, and cloud-based capabilities. Innolitics, known for its work with Fortune 100 companies and Biodesix (NASDAQ: BDSX) shares traded higher after Jack Schulher bought 723,239 and 4,000,000 shares of the company at US$0.341 and US$0.2675, respectively, since last Friday. Shares closed up 46% at US$0.4. Jaguar Health (NASDAQ: JAGX) will raise capital via a direct offering of 246,306 shares at US$6.09/share, and a concurrent private placement of warrants for 492,612 shares at US$5.84/share. Shares closed down 27% at US NeurAxis (NYSE: NRXS) announced a US$5.0M direct offering, selling 1,538,461 common shares at US$3.25/share, priced at market under NYSE American rules. Shares closed down 20% at US$3.2. Quipt Home Medical (NASDAQ: QIPT) received an unsolicited, non-binding proposal from Forager Capital Management to acquire 100% of its common shares at US$3.10 per share. Shares closed down 9% at US$1.95.
V小姐
4 days ago
Global Biotech Weekly
This week we focus on the catalysts due for Phase 1 and 2 trials. At this stage in development, these trials aim to test the safety, side effects, and best dose of a new treatment. Data from these trials can also review initial efficacy data that will then be used to compare with the drug’s efficacy
V小姐
4 days ago
Biotech Stock Updates
We focus to look at key drivers of biotech stocks' price movement on 14 May 2025. Incannex Healthcare (NASDAQ: IXHL) shares closed up 866% at US$0.82 following the completion of patient dosing in the Phase 2 portion of its Phase 2/3 RePOSA study evaluating IHL-42X for obstructive sleep apnea (OSA). Bluebird Bio (NASDAQ: BLUE), Carlyle, and SK Capital amended their acquisition agreement. Bluebird stockholders can now choose between US$3.00 per share plus a US$6.84 CVR upon achieving a sales milestone, or US$5.00 p Aytu BioPharma (NASDAQ: AYTU) reported quarterly earnings of US$0.21 per share, exceeding analyst estimates losses of US$0.17 by 223.5% and marking a 140.4% improvement from last year’s US$0.52 loss. Quarterly sales re Septerna (NASDAQ: SEPN) and Novo Nordisk (NASDAQ: NVO) have entered an exclusive global collaboration to discover, develop, and commercialize oral small-molecule medicines for obesity, type 2 diabetes, and other cardio Plus Therapeutics (NASDAQ: PSTV) is expected to report increased earnings on higher revenue for the quarter ending March 2025. Consensus estimates project a US$0.17 per share loss and US$1.85m in revenue. Surpassing th Quoin Pharmaceuticals (NASDAQ: QNRX) observed clear skin improvement in a pediatric peeling skin syndrome study after 12 weeks. Key endpoints showed significant improvement, and the treatment QRX003 was well-tolerated. Allurion Technologies (NASDAQ: ALUR) shares closed up 26% at US$3 following obesity data. Studies highlighted weight loss and muscle gain with their balloon and AI-powered care, both with and without GLP-1s. Combining
V小姐
1 week ago
Global Biotech Weekly
This week, we will focus on key Phase 3 catalysts left for the quarter anticipated in the immediate term over the next two months. Reviva Pharmaceuticals (NASDAQ: RVPH) is a clinical-stage biopharmaceutical company with a market cap under US$100m. The company is focused on developing therapies targe Brilaroxazine is being developed for schizophrenia, with results from the Phase 3 RECOVER trial showing broad-spectrum efficacy and a favorable long-term safety profile. NovoCure (NASDAQ: NVCR) is a commercial-stage oncology company with a market cap in the mid-single-digit billions, known for its Tumor Treating Fields (TTFields) platfor NovoCure’s Phase 3 PANOVA-3 trial evaluated TTFields combined with nab-paclitaxel and gemcitabine for locally advanced pancreatic cancer. Final results released in Decem Gossamer Bio (NASDAQ: GOSS) is a clinical-stage biopharmaceutical company focused on developing therapies for pulmonary diseases. The company has a small market cap unde Seralutinib is currently being evaluated in the Phase 3 PROSERA trial for PAH, following positive results from the Phase 2 TORREY study, which met its primary endpoint. InflaRx N.V. (NASDAQ: IFRX) is a clinical-stage biotech developing anti-inflammatory therapeutics, with a focus on complement factor C5a inhibition. The company has a sm Vilobelimab is in a pivotal Phase 3 trial for pyoderma gangraenosum (PG), a rare neutrophilic dermatosis. The ongoing study follows a promising Phase 2a dose-finding tri
V小姐
1 week ago
Global Biotech Weekly
As the American Society of Clinical Oncology Conference (ASCO25) approaches, we’re spotlighting key data and late-breaking presentations to watch. With abstracts scheduled for release on 23 May and the conference taking place on 30 May 2025, this preview offers investors ample time to conduct furthe
V小姐
3 weeks ago
Biotech Stock Updates
We focus to look at recent key drivers of biotech stocks' price movement. Relmada Therapeutics (NASDAQ: RLMD) reported Phase 2 results for NDV-01 in non-muscle invasive bladder cancer, with a 90% overall response rate, 89% high-grade recurrence-free survival in papillary disease, and 100% complete r Silo Pharma (NASDAQ: SILO) filed a U.S. patent application for SPC-14, an intranasal Alzheimer’s treatment licensed from Columbia University, covering its novel dual targeting of NMDAR and 5-HT4 receptors to address cognitive Senti Biosciences (NASDAQ: SNTI) reported Phase 1 data for SENTI-202 in relapsed/refractory hematologic malignancies, with a 71% overall response rate across evaluable patients, including complete remissions and MRD negativity UroGen Pharma (NASDAQ: URGN) presented new patient-reported outcomes at AUA2025 showing that UGN-102 maintained bladder function, symptom burden, and quality of life in low-grade intermediate-risk NMIBC patients, reinforcing i Portage Biotech (NASDAQ: PRTG) reported preclinical data showing PORT-7, a selective A2B receptor inhibitor, outperformed anti-PD1 therapy in a mesothelioma model, with combination treatment further enhancing efficacy and prom CG Oncology (NASDAQ: CGON) presented Phase 3 BOND-003 Cohort C data at AUA2025 showing cretostimogene grenadenorepvec achieved a 75.5% complete response rate in high-risk BCG-unresponsive NMIBC, with durable responses lasting ADMA Biologics (NASDAQ: ADMA) announced FDA approval of its yield enhancement process, which increases production yields by approximately 20% from the same starting plasma volume, improving manufacturing efficiency. Tharimmune (NASDAQ: THAR) announced FDA feedback indicating no additional clinical trials are needed before submitting a 505(b)(2) NDA for TH104, a buccal film formulation of nalmefene designed for rapid absorption and potenti
V小姐
4 weeks ago
Biotech Stock Pre-Market Updates
What are the key pre-market updates for biotech stocks? Galmed Pharmaceuticals (NASDAQ: GLMD) announced it has signed a binding term sheet with Entomus s.r.o. for a license agreement to develop and commercialize a proprietary Self-Emulsifying Drug Delivery System (SEDDS) that enables sublingual abso Portage Biotech (NASDAQ: PRTG) reported confirmatory preclinical data showing that PORT-7 (TT-4), a selective adenosine A2B receptor inhibitor, outperformed anti-PD1 antibody treatment in a murine mesothelioma model. The combination of PORT-7 a CG Oncology (NASDAQ: CGON) announced that Phase 3 BOND-003 Cohort C data for cretostimogene grenadenorepvec monotherapy was presented at the 2025 AUA Annual Meeting. In high-risk NMIBC patients unresponsive to BCG, the study showed a 75.5% comp Merck KGaA (NYSE: MRK) and SpringWorks Therapeutics (NASDAQ: SWTX) announced a definitive agreement for Merck KGaA to acquire SpringWorks for US$47 per share in cash, valuing the company at approximately US$3.9bn in equity and US$3.4bn in enter Biohaven (NYSE: BHVN) announced an agreement with Oberland Capital Management LLC for an investment of up to US$600m, with an initial US$250m tranche set to be funded by 30 April 2025. ADMA Biologics (NASDAQ: ADMA) announced FDA approval of its innovative yield enhancement production process. This innovative process has demonstrated an ability to increase production yields by approximately 20% from the same starting plasma vo
V小姐
4 weeks ago
Biotech Stock Updates
We focus to look at key drivers of biotech stocks' price movement on 25 April 2025. Summit Therapeutics (NASDAQ: SMMT) shares closed down 36% at US$23.47 despite China approving Akeso’s ivonescimab (AK112) as a first-line lung cancer monotherapy after a Phase 3 trial showed superior progression-free Molecular Partners (NASDAQ: MOLN) shares traded up 22% at US$5.12 after MP0712, a ²¹²Pb-labeled Radio-DARPin targeting DLL3 for small-cell lung cancer, demonstrated strong preclinical efficacy and safety, with first- VYNE Therapeutics (NASDAQ: VYNE) reported that the FDA verbally informed VYNE Therapeutics that it had placed a clinical hold on the company’s Phase 1b study evaluating VYN202 for treating moderate-to-severe plaque p Acrivon Therapeutics (NASDAQ: ACRV) will present preclinical data at AACR 2025 showing how ACR-2316 a clinical-stage, AP3-enabled WEE1/PKMYT1 inhibitor drives potent single-agent tumor cell death by inducing mitotic BriaCell Therapeutics (NASDAQ: BCTX) priced a US$13.8m public offering of 3.1m units at US$4.50 each, with each unit consisting of one common share and one warrant exercisable at US$5.25. The company intends to use t Lexaria Bioscience (NASDAQ: LEXX) announced that it has entered into a definitive agreement with a single institutional investor for the purchase and sale of 2.0m shares of common stock at a purchase price of US$1.00 Cyclacel Pharmaceuticals (NASDAQ: CYCC) issued a US$0.15 per share quarterly dividend payable on 1st May to shareholders recorded by 29th April, the ex-dividend date. Separately, Cyclacel Pharmaceuticals has been gra
V小姐
4 weeks ago
Global Biotech Weekly
This week, we will focus on the critical near-term catalysts anticipated in the immediate term over the next two months. Nektar Therapeutics (NASDAQ: NKTR) is a biotechnology company with a market cap of about US$196m and a cash balance of approximately US$179m. The company has a history of developi NKTR runs two separate Phase 2b trials with rezpegaldesleukin (LY3471851), an IL-2 pathway agonist. One trial (REZOLVE-AA) targets severe to very severe alopecia areata (AA), with Lyra Therapeutics (NASDAQ: LYRA) is developing therapies for chronic rhinosinusitis (CRS), a highly prevalent inflammatory disease. The company has a market cap of around US$26m a The Phase 3 ENLIGHTEN II trial is evaluating LYR-210 in surgically naïve patients with CRS. This study resumed enrollment on 25 April 2023, and is expected to complete enrollment Theriva Biologics (NYSE: TOVX) is a micro-cap clinical-stage company focused on oncolytic virus therapies, with a market cap of approximately US$5.6m. The company has limited cash The VIRAGE trial is a Phase 2b/3 clinical study of VCN-01 in patients with metastatic pancreatic ductal adenocarcinoma (PDAC), a cancer with extremely poor prognosis. The drug hol
V小姐
4 weeks ago
Biotech Stock Updates
We focus to look at key drivers of biotech stocks' price movement on 23 April 2025.Ensysce Biosciences (NASDAQ: ENSC) received a USPTO Notice of Allowance for a patent covering composition and method claims for PF9001, a methadone prodrug using its TAAP and MPAR technologies to improve safety in opioid use disorder treatment. Shares closed up 96% at US$3.67.
V小姐
1 month ago
Copyright ©2025 Fortress Hill Media limited. All rights reserved